Skip to content
Screener

AtriCure ATRC Q4 2025 Annual earnings

Reported February 17, 2026 · After market close

Revenue$140.5MBeat by $785.4K
EPS$0.06Beat by $0.10
Revenue estimate$139.7M
EPS estimate-$0.04

Next report

Nov 4, 2026 (in 2 months)
Revenue estimate$151.2M
EPS estimate$0.01

Financials

Q4 2025

Income statement

See full
Revenue$140.5M+13.1%
Gross profit$105.3M+13.7%

Balance sheet

See full
Cash & equivalents$167.4M+36.4%
Total debt$77.7M-2.0%
Total equity$491.9M+6.7%
Total assets$654.2M+7.4%

Cash flow

See full
Operating cash flow$20.0M+243%
CapEx$1.6M-40.5%
Free cash flow$18.4M+486%

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$1.97B+32.0%
Enterprise value$1.88B+29.8%
P/S3.7×+0.5×

Profitability

See full
Gross margin75%+0.3pp
FCF margin9%—

Returns & leverage

See full
Debt / equity0.2×0.0×
Current ratio4×+0.3×

Segments

By product

See full
Appendage management$56.9M+14.7%
Open ablation$49.3M+17.4%
Pain management$24.4M+24.4%
Minimally invasive ablation$9.9M-24.3%

By geography

See full
Total International$26.2M+15.3%
Europe$16.0M+16.9%
Other International$1.8M+15.8%

FAQ

When did AtriCure report Q4 2025 earnings?
AtriCure (ATRC) reported Q4 2025 earnings on February 17, 2026 after market close.
What were AtriCure's Q4 2025 revenue and EPS?
AtriCure reported revenue of $140.5M and eps of $0.06 for Q4 2025.
Did AtriCure beat estimates in Q4 2025?
Revenue beat the consensus estimate of $139.7M by $785.4K. EPS beat the consensus estimate of $-0.04 by $0.10.
How did AtriCure's Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 13.1% from $124.3M a year earlier.
Where can I find AtriCure's Q4 2025 SEC filings?
You can read the 8-K earnings release (0001323885-26-000005) and the 10-K periodic report (0001323885-26-000007) directly on SEC EDGAR. The filing index links above go to sec.gov.